<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03839420</url>
  </required_header>
  <id_info>
    <org_study_id>929MP BER-401-18</org_study_id>
    <nct_id>NCT03839420</nct_id>
  </id_info>
  <brief_title>To Compare Early Rotation of Two Extended Depth of Focus Intraocular Lenses</brief_title>
  <acronym>VENUStoric</acronym>
  <official_title>Prospective Randomized Clinical Trial Comparing Early Rotation of Two Extended Depth of Focus Intraocular Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl Zeiss Meditec AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carl Zeiss Meditec AG</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that the Carl Zeiss Meditec (CZM) Extended depth of focus (EDOF) Intraocular
      lens (IOL) is superior to the competitor EDOF IOL with respect to Rotational Stability.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>comparative randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IOL axis</measure>
    <time_frame>Immediately after the surgery</time_frame>
    <description>IOL axis will be analyzed based on images.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>CZM IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Competitor IOL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CZM IOL</intervention_name>
    <description>implantation of CZM IOL</description>
    <arm_group_label>CZM IOL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Competitor IOL</intervention_name>
    <description>implantation of Competitor IOL</description>
    <arm_group_label>Competitor IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient informed of the consequences and constraints of the Clinical Investigational
             Plan and who has given his/her written informed consent

          2. Patients of any gender, aged 18 or older

          3. Assured follow-up examinations

          4. Healthy eyes with clinically significant age related cataract requiring surgical
             treatment

          5. Corrected distance visual acuity projected to be better than 0.2 logMAR after the
             cataract surgery, as determined by Investigator's medical judgment

          6. Uni- and/or bilaterally regular corneal astigmatism ≥ 1.0 D and ≤ 3.0 D (confirmed by
             topography measurement)

        8. Cataract density compatible with biometry measurement

        Exclusion Criteria:

          1. Patients unable to meet the limitations of the Clinical Investigational Plan or likely
             of non-cooperation during the trial

          2. Patients whose freedom is impaired by administrative or legal order

          3. Current participation in another drug or device investigation that affects patients
             vision

          4. Ocular disorders, other than cataract, that could potentially cause future acuity loss

          5. Have atonic pupil or physiologically small pupil (unable to dilate to at least 5 mm)

          6. Any anterior segment pathology that could significantly affect outcomes (e.g. chronic
             or recurrent uveitis, iritis, aniridia, rubeosis iridis, etc.)

          7. Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal
             degeneration, or irregular astigmatism, clinically significant corneal membrane
             dystrophies)

          8. Any condition in the study eye that could affect IOL stability (e.g. zonular dialysis,
             evident zonular weakness or dehiscence, Floppy iris syndrome etc.)

          9. History of any clinically significant retinal pathology or ocular diagnosis (e.g.
             diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment,
             optic neuropathy optic nerve atrophy, amblyopia, strabismus, microphthalmus,
             epiretinal membrane, Choroidal hemorrhage etc.) in the study eyes that could alter or
             limit final postoperative visual prognosis

         10. Pseudoexfoliation syndrome (according to investigator decision)

         11. Pathologic miosis or Pharmacotherapy with miotic agent

         12. Irregular astigmatism / Keratoconus

         13. Uncontrolled glaucoma or IOP higher than 24mmHg under ocular hypertension treatment.

         14. All kind of infections (acute ocular disease, external / internal infection, systemic
             infection)

         15. Traumatic cataract

         16. Monophthalmic patient

         17. Patients, who are unable to fixate for a longer time, e.g. strabismus, nystagmus

         18. Patient expected to require retinal laser treatment before the end of the last
             follow-up examination

         19. Patient expected to require refractive laser treatment / refractive laser touch-up
             before the end of the last follow-up examination

         20. Previous intraocular and corneal / refractive surgery

         21. Current Systemic or ocular pharmacotherapy that effects patients vision (according to
             investigator decision)

         22. Dementia

         23. Previous use of cytotoxic drugs or total body irradiation within last 2 years

         24. Any other pathology or condition presenting, according to the investigator opinion, a
             risk for the patient

         25. Pregnancy and / or lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Estelle Poineau</last_name>
    <phone>0546523154</phone>
    <email>estelle.poineau@zeiss.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UNIVERSITÄTSKLINIKUM FREIBURG</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

